Nitric oxide synthase gene therapy - GenVec

Drug Profile

Nitric oxide synthase gene therapy - GenVec

Alternative Names: Genstent; iNOS gene therapy - GenVec

Latest Information Update: 18 Mar 2003

Price : $50

At a glance

  • Originator GenVec
  • Class Gene therapies
  • Mechanism of Action Nitric oxide synthase stimulants; Nitric oxide synthase type II inhibitors; Nitric oxide synthase type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Vascular graft occlusion; Vascular restenosis

Most Recent Events

  • 18 Mar 2003 Discontinued - Preclinical for Vascular graft occlusion in USA (Intra-arterial)
  • 18 Mar 2003 Discontinued - Preclinical for Vascular restenosis in USA (Intra-arterial)
  • 22 May 2001 Preclinical development for Vascular graft occlusion in USA (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top